Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
此前报道，BrainStorm Cell Therapeutics宣布管理层变动，计划对NuroWN进行3b期注册试验
- Bob Dagher, MD, Promoted to Chief Medical Officer
- Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors
- 鲍勃·达格尔，医学博士，晋升为首席医疗官
- Stacy Lindborg博士卸任联席首席执行官并过渡到董事会
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。